Signal transducer and activator of transcription 6 as a target in colon cancer therapy (Review)
- Yael Delgado‑Ramirez
- Vaneesa Colly
- Giovanni Villanueva Gonzalez
- Sonia Leon‑Cabrera
Affiliations: Laboratory of Oncoimmunology, Biomedical Research Unit, National Autonomous University of Mexico, Tlalnepantla, CP 54090, Mexico, Medical School, Faculty of Superior Studies Iztacala, National Autonomous University of Mexico, Tlalnepantla, CP 54090, Mexico
- Published online on: May 13, 2020 https://doi.org/10.3892/ol.2020.11614
Copyright: © Delgado‑Ramirez
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Signal transducer and activator of transcription 6 (STAT6) is a member of the STAT family of proteins that serve key roles in the initiation of tumorigenesis and malignant transformation. STAT6 is highly expressed in several types of cancer, including breast, pancreatic, prostate and colorectal cancer. STAT6 transduces signals in response to the binding of interleukin (IL)‑4 and IL‑13 to their receptors and regulates the expression of genes involved in the immune response, cell survival, tumor proliferation and metastasis. Patients with colorectal cancer exhibit high STAT6 activity in the colonic epithelium, and STAT6 expression is associated with lower survival rates, lymph node metastasis, changes in the epithelial barrier function and alterations in the inflammatory response. A number of studies investigating experimental models and cancer cell lines have revealed that STAT6 is associated with tumor growth and development, as well as with increased invasion and metastasis, suggesting that STAT6 inhibition may serve as a novel therapeutic strategy in colon cancer. The present review summarizes the evidence with regard to the implications of STAT6 in cancer biology and the direct and indirect effects on colon tumor transformation. Furthermore, the current treatment strategies targeting the IL‑4/IL‑13/STAT6 axis in colon cancer are discussed.